EPZ-5676 disrupts the methylation-driven activation of oncogenes and has shown promising anti-leukemic effects in preclinical models, positioning it as a potential targeted therapy for MLL-rearranged leukemia. The gene discussed is KMT2A; the disease is leukemia.